Wells Fargo lowered the firm’s price target on Bristol-Myers to $65 from $78 and keeps an Equal Weight rating on the shares. Bristol-Myers’ lowered top-line guidance of low single-digit decline casts a wide net, and there could be more decline built in than just to Revlimid and Pomalyst, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- Bristol-Myers price target lowered to $80 from $85 at BofA
- Bristol-Myers price target lowered to $62 from $64 at Barclays
- 2seventy Bio downgraded to Equal Weight from Overweight at Morgan Stanley
- Cutera upgraded to Neutral at Piper after CEO appointment
- Bristol-Myers Squibb (NYSE:BMY) Tanks on Q2 Miss; Guidance Disappoints